AZTA
Azenta, Inc. NASDAQ$24.33
Mkt Cap $1.1B
52w Low $19.87
20.4% of range
52w High $41.73
50d MA $23.70
200d MA $30.34
P/E (TTM)
-20.4x
EV/EBITDA
21.2x
P/B
0.7x
Debt/Equity
0.1x
ROE
2.7%
P/FCF
34.3x
RSI (14)
—
ATR (14)
—
Beta
1.47
50d MA
$23.70
200d MA
$30.34
Avg Volume
961.6K
About
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological samp…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | AMC | 0.11 | 0.09 | -18.2% | 28.49 | -1.8% | -2.2% | +0.8% | +4.6% | +5.3% | +6.9% | — |
| Nov 21, 2025 | AMC | 0.19 | 0.21 | +10.8% | 34.89 | +0.7% | +5.2% | +9.2% | +4.0% | +1.9% | -0.1% | — |
| Aug 5, 2025 | AMC | 0.13 | 0.19 | +46.2% | 26.90 | +4.0% | +5.6% | +8.3% | +7.9% | +4.0% | +8.6% | — |
| May 7, 2025 | AMC | 0.09 | 0.05 | -44.4% | 25.26 | +3.0% | +9.7% | +6.0% | +12.0% | +10.5% | +6.7% | — |
| Feb 5, 2025 | AMC | 0.05 | 0.08 | +60.0% | 53.76 | +1.2% | +0.5% | -2.7% | -11.6% | -14.7% | -15.7% | — |
| Nov 12, 2024 | AMC | 0.11 | 0.18 | +63.6% | 45.99 | +4.1% | -3.2% | -7.3% | -9.7% | -12.2% | -11.0% | — |
| Aug 6, 2024 | AMC | 0.07 | 0.16 | +128.6% | 58.34 | +3.9% | -8.9% | -4.2% | -5.3% | -6.8% | -6.9% | — |
| May 8, 2024 | AMC | 0.02 | 0.05 | +167.6% | 54.07 | -5.4% | -2.9% | -4.6% | -5.0% | -5.2% | -4.6% | — |
| Feb 7, 2024 | AMC | 0.01 | 0.02 | +159.7% | 65.05 | -1.6% | -1.6% | +0.1% | +1.4% | -1.9% | +0.9% | — |
| Nov 13, 2023 | AMC | 0.02 | 0.13 | +629.3% | 47.81 | +11.7% | +13.9% | +13.2% | +14.1% | +15.4% | +17.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $22.63 | $22.61 | -0.1% | -0.2% | -4.1% | -1.5% | +0.1% | -1.9% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $20.91 | $20.94 | +0.1% | +5.4% | +3.2% | -1.3% | -3.4% | -2.2% |
| Feb 5 | Evercore ISI | Maintains | Outperform → Outperform | — | $28.49 | $27.97 | -1.8% | -2.2% | +0.8% | +4.6% | +5.3% | +6.9% |
| Feb 4 | Jefferies | Maintains | Buy → Buy | — | $36.91 | $32.05 | -13.2% | -22.8% | -24.5% | -22.2% | -19.3% | -18.7% |
| Feb 4 | Needham | Maintains | Buy → Buy | — | $36.91 | $32.05 | -13.2% | -22.8% | -24.5% | -22.2% | -19.3% | -18.7% |
| Jan 8 | TD Cowen | Maintains | Hold → Hold | — | $37.51 | $37.21 | -0.8% | -0.0% | +1.1% | +0.1% | +2.6% | +5.3% |
| Jan 5 | Evercore ISI | Upgrade | In Line → Outperform | — | $33.39 | $34.25 | +2.6% | +7.1% | +10.8% | +12.3% | +12.3% | +13.6% |
| Dec 19 | Needham | Maintains | Buy → Buy | — | $34.50 | $34.43 | -0.2% | -0.2% | +0.6% | +0.6% | +0.0% | +0.7% |
| Nov 25 | Raymond James | Maintains | Outperform → Outperform | — | $36.70 | $36.93 | +0.6% | +3.8% | -1.2% | -3.1% | -5.0% | -4.2% |
| Nov 21 | Needham | Maintains | Buy → Buy | — | $30.00 | $34.00 | +13.3% | +16.3% | +22.3% | +27.0% | +20.9% | +18.5% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced life sciences executive is joining one of these companies, likely signaling leadership transition or strategic expansion in biotech/pharma sectors, which could impact growth direction and investor confidence.
Apr 7
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
AZTA's proposed transaction faces financing risk and may not close as planned, creating uncertainty about the deal's completion that could significantly impact the stock price.
Apr 2
8-K · 1.01
!! High
Azenta, Inc. -- 8-K 1.01: Material Agreement
Azenta signed a material agreement with Antony Co., though specific terms remain undisclosed, potentially impacting the company's operations or financial position pending further details.
Mar 4
8-K
Azenta, Inc. -- 8-K Filing
Azenta reported its first quarter fiscal 2026 results for the period ended December 31, 2025, providing investors with updated financial performance metrics and operational insights.
Feb 4
8-K · 5.02
!!! Very High
Azenta, Inc. -- 8-K 5.02: Executive Change
Alan P. Malus's resignation as Azenta director effective January 29, 2026, represents a minor board composition change with limited immediate impact on the biopharmaceutical services company's operations or strategy.
Feb 2
Data updated apr 24, 2026 8:21pm
· Source: massive.com